|
|
Volumn 17, Issue 8, 2016, Pages e322-
|
|
Tasquinimod treatment for prostate cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IMMUNOLOGICAL ANTINEOPLASTIC AGENT;
QUINOLONE DERIVATIVE;
TASQUINIMOD;
DISEASE FREE SURVIVAL;
HUMAN;
MALE;
MORTALITY;
PATHOLOGY;
PHASE 3 CLINICAL TRIAL (TOPIC);
PROSTATE TUMOR;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL;
CLINICAL TRIALS, PHASE III AS TOPIC;
DISEASE-FREE SURVIVAL;
HUMANS;
MALE;
PROSTATIC NEOPLASMS;
QUINOLONES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TREATMENT OUTCOME;
|
|
EID: 85010292694
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/S1470-2045(16)30272-8 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|